Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...
Health researchers working with DENT Neurologic Institute, Jamaica pharmaceutical company to increase global clinical research.
This voluntary consensus standard outlines best practices for hazard communication, regulatory compliance, and training.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback